alexa Cytotoxicity of Nutritional Supplement Galaxy® against HepG2 Hepatocellular Carcinoma
ISSN: 2327-5162

Alternative & Integrative Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Cytotoxicity of Nutritional Supplement Galaxy® against HepG2 Hepatocellular Carcinoma

David B Jeffs, Alexander C Martin, Erick R Rosenvall, Tyson Fillmore, Katelyn E Barrett and Gary M Booth*

Brigham Young University, Department of Plant and Wildlife Sciences, Provo, Utah 84602, USA

*Corresponding Author:
Gary M Booth
Professor of Plant and Wildlife Sciences
Brigham Young University
5113 Life Science Building
Provo, Utah 84602, USA
Tel: 801-636-6363
E-mail: [email protected]

Received date June 18, 2014; Accepted date November 7, 2014; Published date November 9, 2014

Citation: Jeffs DB, Martin AC, Rosenvall ER, Fillmore T, Barrett KE, et al. (2014) Cytotoxicity of Nutritional Supplement Galaxy® against HepG2 Hepatocellular Carcinoma. Altern Integ Med 3:175. doi:10.4172/2327-5162.1000175

Copyright: © 2014 Jeffs DB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Current treatment for hepatocellular carcinoma consists of chemotherapy and invasive tumor removal surgery. These forms of treatment have often been disappointing while new and natural methods to treat liver cancer may be preferred. We tested the cytotoxic effects of the fruit mixture Galaxy® against HepG2 hepatocellular carcinoma cells in vitro. Galaxy® was evaluated using three groups; thus, cytotoxicity bioassays were determined against: whole product (unfractionated), the supernatant, and the particulates. Paclitaxel, a major FDA-approved chemotherapeutic drug, was tested against HepG2 cells in order to compare the effectiveness of the Galaxy® matrices against traditional chemotherapy. In addition, a 24-hour bioassay was performed to compare the toxicity of Galaxy® each hour through the incubation period. Our results have shown that unfractionated Galaxy® has significant anticancer activity in vitro against HepG2 hepatocellular carcinoma, killing 90% of cancer cells at 26.3 mg/mL. The particulates and supernatant fractions were also cytotoxic on liver cancer. The majority of anticancer activity was present in the particulate fraction which suggests that most of the anticancer agents are located primarily in the pulp and are membrane bound. While Galaxy® is not as effective as Paclitaxel at lower concentrations; our in vitro results clearly show that Galaxy® (all three matrices) may be an effective product against human hepatocellular carcinoma at higher concentrations. During the 24-hour cycle study, unfractionated Galaxy® showed a steady linear cytotoxic effect per hour. Collectively the data from these experiments suggest that Galaxy® merits serious consideration in the development of future research protocols.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords